Corporate VCs Wade In With Funds To Pursue Gene Therapy For Wilson Disease

Potential new treatments for the for the rare, inherited metabolic condition Wilson disease are hoping to fill the unmet need in the disease despite the availability of older products that chelate copper in the blood. Just recently a new copper chelator was given a green light by the EMA's advisory committee (gmp-orphan's Cuprior (trientine base). Meanwhile, Swedish biotech Wilson Therapeutics AB recently reported positive Phase II data with its copper modulating agent WTX101 (bis-choline tetrathiomolybdate), a novel approach to treating the condition. (Also see "Wilson Therapeutics Progressing Its Copper Modulating Agent To Phase III" - Scrip, 5 December, 2016.)

But Vivet Therapeutics hopes to go further and treat the underlying genetic error that causes the disease. It has raised €37